IBEX (IBEX) Q4 2026 Earnings Call Transcript

IBEX delivered record FY2026 revenue of $644.1 million, up 15.4% organically, and adjusted EBITDA of $82.4 million, up 14.5%, while free cash flow reached a record $31.2 million. Q4 revenue increased 11.6% to $164.3 million, marking the sixth consecutive quarter of double-digit growth, although Q4 adjusted EBITDA margin declined to 12.3% from 13.9% due to client-training costs, delivery-center transitions, and higher fuel expenses. FY2027 guidance calls for $700 million-$715 million of revenue and $90 million-$94 million of adjusted EBITDA, implying 9%-11% and 9%-14% growth, respectively. HealthTech revenue exceeded its target at $114 million, up 38.5%, while AI-agent deployments are supporting new client wins and expansion opportunities.

Analysis

IBEX's central investment question is whether AI-enabled delivery raises wallet share faster than it removes labor hours. The early deployments support a land-and-expand model, but management has not disclosed AI-specific pricing, gross margin, or revenue mix; without these, investors should not capitalize the AI narrative at a SaaS-like multiple. Near term, the more tangible catalyst is conversion of the unusually strong new-logo cohort into billable production, which should unwind training drag and support sequential margin recovery over the next 1-3 months.

The earnings-quality caveat is that FY27 EBITDA growth is broadly in line with revenue despite favorable mix claims, while normalized taxes will rise materially versus the recent reported rate and capex remains elevated. This makes free-cash-flow conversion—not adjusted EBITDA—the key underwriting metric over the next two quarters. Offshore expansion improves structural labor economics, but also concentrates exposure to wage inflation, FX, utility costs, geopolitical disruption, and client scrutiny of data-security controls in healthcare and financial-services workflows.

Competitive dynamics favor scaled providers that can bundle human support, implementation, and automation, pressuring traditional BPO peers such as G and CSGS. The contrarian view is that IBEX may be more defensible than the market assumes because AI vendors need operational data, workflow integration, and regulated-industry delivery capacity; conversely, the company could become a lower-margin channel partner if Sierra or another platform captures the software economics. The stock's valuation and post-call move are not supplied, so a directional entry should be conditional rather than chased.

Key Decisions for Investors

• Place IBEX on a 1-3 month long watch: initiate only if the next report shows adjusted EBITDA margin recovering above the recent trough while revenue growth remains at or above low-double digits; target a 15-20% upside move on multiple stabilization and operating leverage, with thesis invalidated by a second consecutive margin decline or reduced full-year guidance.
• For a relative expression, consider long IBEX / short G in equal dollar amounts after confirming IBEX trades at no more than a modest premium to G on forward EV/EBITDA. The thesis is share capture and AI-enabled implementation velocity; exit if IBEX's new-logo conversion stalls or AI deployments fail to translate into disclosed revenue growth.
• Do not underwrite FY27 EPS off the prior favorable tax rate. Update models to the normalized tax range and track free cash flow after capex; a shortfall versus this metric, rather than EBITDA alone, is the clearest signal that capacity investment is consuming the expected returns.
• Monitor customer-concentration and AI-unit-economics disclosure at the next earnings call: request retained revenue, pricing model, gross margin, and implementation costs for AI contracts. Absence of this disclosure after several scaled deployments is a yellow flag and argues against paying an AI premium.